First Clinical Cases at The University of Kansas Hospitalutilizing theAdvanced Perfusor® Syringe Pump for Adenocaine

ATLANTA--(BUSINESS WIRE)-- Hibernation Therapeutics USA, LLC (HT) has partnered with B. Braun Medical Inc. (B.Braun) to introduce an innovative, low-cost syringe pump delivery system for the administration of its patented Adenocaine® Hiberplegia™ solution, the world’s first non-depolarizing cardioplegia.

For the first time, cardiac surgeons at The University of Kansas Hospital (KUMED), Kansas City, KS, USA successfully administered Adenocaine® Hiberplegia™ solution using the B.Braun Perfusor® Space syringe pump to aid in the arrest and protection of the heart during open heart surgery. “In our initial clinical cases, we have observed improved cardioprotection in some very difficult cases,” stated Gregory F. Muehlebach, MD at KUMED, “and we are collecting additional data to better understand the clinical benefit of the Adenocaine® cardioplegia.”

Adenocaine®’s polarizing patented formulation has shown superior myocardial protection and improved outcomes in preclinical studies and physicians are observing similar results during clinical use, in comparison to standard high potassium depolarizing cardioplegia. According to HT’s CSO and James Cook University Professor Geoffrey P. Dobson: “The Adenocaine® technology places the heart in a more 'natural' state of suspended animation similar to that of a hibernating animal, making cardiac surgery safer for the patient, more predictable for the surgeon and economically compelling for hospitals and other purchasers of health care.”

“By incorporating the B.Braun Perfusor® Space pump with its custom Adenocaine® drug library, clinicians can easily integrate the delivery of Adenocaine® into any existing cardioplegia delivery system and at any blood:cardioplegia ratio the perfusionist prefers,” said David C. Field, CEO for HT. “This user-friendly, cost-effective syringe pump delivery system now makes the Adenocaine® solution available and affordable to any hospital.”

Adenocaine® Hiberplegiasolution is available exclusively through Central Admixture Pharmacy Services (CAPS®).

For more information on CAPS, please visit www.capspharmacy.com/Adenocaine

Adenocaine is a registered trademark of Hibernation Therapeutics Global, Ltd.

Hiberplegia is a trademark of Hibernation Therapeutics Global, Ltd.

For more information on Hibernation Therapeutics, its Adenocaine® technologies and intellectual property, please visit www.Adenocaine.com.



CONTACT:

For Hibernation Therapeutics
Beth Wilson, 478-744-9994 ext. 6211
[email protected]

KEYWORDS:   United States  North America  Georgia  Kansas

INDUSTRY KEYWORDS:   Surgery  Health  Cardiology  Clinical Trials  Hospitals  Pharmaceutical  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.